⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128777 | 1.00 | — | — | |
| SCHEMBL29241305 | 0.79 | METAP2 (0.32) | — | |
| SCHEMBL913618 | 0.70 | — | — | |
| SCHEMBL913440 | 0.70 | PDE5A (0.30) | — | |
| SCHEMBL2042751 | 0.69 | PIK3CG (0.37) | — | |
| SCHEMBL2005965 | 0.68 | — | — | |
| SCHEMBL30131113 | 0.65 | — | — | |
| SCHEMBL15677263 | 0.65 | — | — | |
| SCHEMBL3650449 | 0.65 | — | — | |
| SCHEMBL2005810 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344372-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118255773-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118255774-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4355747-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT FOR THE TREATMENT OF DISEASES SUCH AS CANCER | JANSSEN Pharmaceutica NV (BE) | 2024-04-24 | — | — | EP | disclosed |
| EP-4347600-A1 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | JANSSEN Pharmaceutica NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117730081-A | Substituted spirocyclic derivatives | 詹森药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4334310-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN Pharmaceutica NV (BE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334320-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN Pharmaceutica NV (BE) | 2024-03-13 | — | — | EP | disclosed |
| CN-110740996-B | Covalent small molecule DCN1 inhibitors and methods of treatment using the same | 密执安大学评议会 | 2024-01-09 | — | — | CN | disclosed |
| CN-117321049-A | Substituted spirocyclic derivatives | 詹森药业有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-110248946-B | Azepan inhibitors of the Menin-MLL interaction | 詹森药业有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-111601807-B | Exo-azaspiro inhibitors of MENIN-MLL interactions | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022262796-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-M ETHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT FOR THE TREATMENT OF DISEASES SUCH AS CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022237627-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237626-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| EP-4077312-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867721-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |